PL2089024T3 - Kombinacja inhibitorów IAP i inhibitorów FLT3 - Google Patents

Kombinacja inhibitorów IAP i inhibitorów FLT3

Info

Publication number
PL2089024T3
PL2089024T3 PL07868853T PL07868853T PL2089024T3 PL 2089024 T3 PL2089024 T3 PL 2089024T3 PL 07868853 T PL07868853 T PL 07868853T PL 07868853 T PL07868853 T PL 07868853T PL 2089024 T3 PL2089024 T3 PL 2089024T3
Authority
PL
Poland
Prior art keywords
combination
inhibitors
iap
flt3
active agents
Prior art date
Application number
PL07868853T
Other languages
English (en)
Polish (pl)
Inventor
James Douglas Griffin
Leigh Zawel
Original Assignee
Novartis Ag
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Dana Farber Cancer Inst Inc filed Critical Novartis Ag
Publication of PL2089024T3 publication Critical patent/PL2089024T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07868853T 2006-11-28 2007-11-27 Kombinacja inhibitorów IAP i inhibitorów FLT3 PL2089024T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US89108807P 2007-02-22 2007-02-22
EP07868853A EP2089024B1 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors
PCT/US2007/085579 WO2008067280A2 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors

Publications (1)

Publication Number Publication Date
PL2089024T3 true PL2089024T3 (pl) 2011-10-31

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07868853T PL2089024T3 (pl) 2006-11-28 2007-11-27 Kombinacja inhibitorów IAP i inhibitorów FLT3

Country Status (20)

Country Link
US (1) US8492429B2 (cg-RX-API-DMAC10.html)
EP (1) EP2089024B1 (cg-RX-API-DMAC10.html)
JP (1) JP5394249B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090087094A (cg-RX-API-DMAC10.html)
AT (1) ATE509629T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007325280B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0719543A2 (cg-RX-API-DMAC10.html)
CA (1) CA2670498A1 (cg-RX-API-DMAC10.html)
CO (1) CO6210722A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP099472A (cg-RX-API-DMAC10.html)
GT (1) GT200900142A (cg-RX-API-DMAC10.html)
IL (1) IL198551A0 (cg-RX-API-DMAC10.html)
MA (1) MA30966B1 (cg-RX-API-DMAC10.html)
MX (1) MX2009005621A (cg-RX-API-DMAC10.html)
NO (1) NO20092417L (cg-RX-API-DMAC10.html)
PL (1) PL2089024T3 (cg-RX-API-DMAC10.html)
PT (1) PT2089024E (cg-RX-API-DMAC10.html)
RU (1) RU2456983C2 (cg-RX-API-DMAC10.html)
TN (1) TN2009000206A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008067280A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EP3928780A4 (en) 2019-02-22 2022-12-07 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
EP3991733A4 (en) 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
US20090005411A1 (en) 2005-12-20 2009-01-01 Novartic Ag Combinations of Organic Compounds
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
CO6210722A2 (es) 2010-10-20
JP5394249B2 (ja) 2014-01-22
RU2456983C2 (ru) 2012-07-27
TN2009000206A1 (en) 2010-10-18
JP2010511059A (ja) 2010-04-08
PT2089024E (pt) 2011-08-31
US20100056467A1 (en) 2010-03-04
ATE509629T1 (de) 2011-06-15
EP2089024A2 (en) 2009-08-19
BRPI0719543A2 (pt) 2014-02-25
WO2008067280A2 (en) 2008-06-05
RU2009124590A (ru) 2011-01-10
WO2008067280A3 (en) 2008-08-07
NO20092417L (no) 2009-08-25
IL198551A0 (en) 2010-02-17
AU2007325280B2 (en) 2011-03-10
KR20090087094A (ko) 2009-08-14
ECSP099472A (es) 2009-10-30
MA30966B1 (fr) 2009-12-01
AU2007325280A1 (en) 2008-06-05
MX2009005621A (es) 2009-06-12
CA2670498A1 (en) 2008-06-05
US8492429B2 (en) 2013-07-23
EP2089024B1 (en) 2011-05-18
GT200900142A (es) 2010-06-24

Similar Documents

Publication Publication Date Title
IL198551A0 (en) Combination of iap inhibitors and flt3 inhibitors
MX2009005551A (es) Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
ZA200701629B (en) Gyrase inhibitors and uses thereof
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
MX372951B (es) Composiciones y metodos de tratamiento que comprenden ceftarolina.
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
WO2007044180A3 (en) Improved toleration iron supplement compositions
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
MX2009005125A (es) Pirrolo[1,2-a]imidazoldiona efectiva en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos.
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
CA2610046A1 (en) Antimicrobial composition useful for preserving wood